PyInvesting

Market research

56S1.F Sartorius Stedim Biotech S.A

F EUR Healthcare

Latest close

232.00 —

As of Nov 19, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
22B
P/E ratio
68.23
Analyst target
Not available
Dividend yield
0.0%
Beta
1.18

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Sartorius Stedim Biotech S.A is currently in a long term uptrend where the price is trading 27.7% above its 200 day moving average.

From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 16.9.

Sartorius Stedim Biotech S.A's total revenue rose by 45.8% to $531M since the same quarter in the previous year.

Its net income has increased by 107.4% to $114M since the same quarter in the previous year.

Finally, its free cash flow fell by 84.4% to $8M since the same quarter in the previous year.

Based on the above factors, Sartorius Stedim Biotech S.A gets an overall score of 4/5.